Last checked at 3 Nov 2022 15:20
REACH: non-regulatory announcement
3 November 2022
ADVANCED ONCOTHERAPY PLC
("Advanced Oncotherapy" or the "Company")
Investor / Analyst Event Update
Advanced Oncotherapy (AIM: AVO), the developer of LIGHT, the next generation proton therapy system for cancer treatment, announces that due to the high number of requests to attend the event, as well as the impact of the rail strikes planned next week affecting travel to/ from the Company's assembly site at Daresbury on Tuesday, 8 November, the Company is scheduling an additional investor/ analyst event on Tuesday, 22 November for those not able to attend the one scheduled next week.
To register your interest in attending this additional event on Tuesday, 22 November, or the event on Tuesday, 8 November, please contact ir@avo-adam.com. The events will be held in person and will also include a tour of the site's technical area including the first operational LIGHT system. Due to health and safety restrictions in the technical area of the LIGHT system the total number of visitors is limited and therefore any application to attend the event will be subsequently confirmed based on the total number of registrations received.
The presentation will be available on the Company's website on 8 November 2022, the day of the first event.
For more information on LIGHT, please see this video explaining the technology.
The full agenda for both events is as follows:
Presentation | Time (GMT) |
Arrival at Daresbury | 12:45 |
Presentation by the Company's management including: | 13:00 - 14:00 |
Nicolas Serandour, Chief Executive Officer | |
Prof. Steve Myers. Executive Chairman ADAM S.A. | |
Ed Lee, Chief Operating Officer | |
Moataz Karmalawy, Chief Commercial Officer | |
Jonathan Farr, Chief Clinical Officer | |
Tour of the technical area and LIGHT system | 14:00 - 15:30 |
Q&A | 15:30 - 16:30 |
- ENDS -
Advanced Oncotherapy plc | www.avoplc.com |
Dr. Michael Sinclair, Executive Chairman | Tel: +44 (0) 20 3617 8728 |
Nicolas Serandour, CEO |
|
| |
Allenby Capital Limited (Nomad and Joint Broker) | |
Nick Athanas / Piers Shimwell (Corporate Finance) Amrit Nahal / Matt Butlin (Sales and Corporate Broking) | Tel: +44 (0) 20 3328 5656 |
SI Capital Ltd (Joint Broker) |
|
Nick Emerson | Tel: +44 (0) 1483 413 500 |
Jon Levinson | Tel: +44 (0) 20 3871 4066 |
| |
FTI Consulting (Financial PR & IR) | advancedoncotherapy@fticonsulting.com |
Simon Conway / Rob Winder | Tel: +44 (0) 20 3727 1000 |
Notes to Editors
About Advanced Oncotherapy Plc
Advanced Oncotherapy, a UK headquartered company with offices in London, Geneva, The Netherlands and in the USA, is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy's team "ADAM," based in Geneva, focuses on the development of a proprietary proton accelerator called, Linac Image Guided Hadron Technology (LIGHT). LIGHT's compact configuration delivers proton beams in a way that facilitates greater precision and electronic control.
Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with innovative technology as well as expected lower treatment-related side effects.
Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.
About Reach announcements
This is a Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.